Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
hypofractionation
image-guided radiotherapy
non-small cell lung cancer (NSCLC)
pulmonary function
thoracic radiotherapy
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
revised:
28
01
2022
received:
05
10
2021
accepted:
01
03
2022
pubmed:
14
4
2022
medline:
24
5
2022
entrez:
13
4
2022
Statut:
ppublish
Résumé
The objective of this study was to investigate the feasibility and efficacy of image-guided moderately hypofractionated thoracic radiotherapy (hypo-IGRT) in patients with non-small cell lung cancer (NSCLC) with poor performance status and severely limited pulmonary function and reserve. Consecutive inoperable patients who had node-positive, stage IIB-IIIC (TNM, 8th edition) or recurrent NSCLC, had an Eastern Cooperative Oncology Group performance status ≥1, and had a forced expiratory volume in 1 second (FEV Between 2014 and 2021, 47 consecutive patients with a median age of 72 years (range, 52.2-88 years) were treated. At baseline, the median FEV Patients with inoperable node-positive NSCLC, a poor performance status, and severely limited lung function can be safely and effectively treated with individualized moderately hypofractionated IGRT. The achieved survival rates for this highly multimorbid group of patients were encouraging.
Sections du résumé
BACKGROUND
The objective of this study was to investigate the feasibility and efficacy of image-guided moderately hypofractionated thoracic radiotherapy (hypo-IGRT) in patients with non-small cell lung cancer (NSCLC) with poor performance status and severely limited pulmonary function and reserve.
METHODS
Consecutive inoperable patients who had node-positive, stage IIB-IIIC (TNM, 8th edition) or recurrent NSCLC, had an Eastern Cooperative Oncology Group performance status ≥1, and had a forced expiratory volume in 1 second (FEV
RESULTS
Between 2014 and 2021, 47 consecutive patients with a median age of 72 years (range, 52.2-88 years) were treated. At baseline, the median FEV
CONCLUSIONS
Patients with inoperable node-positive NSCLC, a poor performance status, and severely limited lung function can be safely and effectively treated with individualized moderately hypofractionated IGRT. The achieved survival rates for this highly multimorbid group of patients were encouraging.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2358-2366Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. doi:10.3322/CAAC.21660
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350. doi:10.1056/nejmoa1809697
Yusuf D, Walton RN, Hurry M, Farrer C, Bebb DG, Cheung WY. Population-based treatment patterns and outcomes for stage III non-small cell lung cancer patients: a real-world evidence study. Am J Clin Oncol. 2020;43:615-620. doi:10.1097/COC.0000000000000716
Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys. 2000;46:516-517. doi:10.1016/S0360-3016(99)00364-8
Zhu ZF, Fan M, Wu KL, et al. A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol. 2011;98:304-308. doi:10.1016/j.radonc.2011.01.022
Cannon DM, Mehta MP, Adkison JB, et al. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013;31:4343-4348. doi:10.1200/JCO.2013.51.5353
Parisi E, Genestreti G, Sarnelli A, et al. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. Radiat Oncol. 2019;14:112. doi:10.1186/s13014-019-1317-x
Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol. 2012;7:33. doi:10.1186/1748-717X-7-33
Pollom EL, Qian Y, Durkee BY, et al. Hypofractionated intensity-modulated radiotherapy for patients with non-small-cell lung cancer. Clin Lung Cancer. 2016;17:588-594. doi:10.1016/j.cllc.2016.05.024
Valeriani M, Marinelli L, Nicosia L, et al. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction). Radiol Med. 2019;124:1324-1332. doi:10.1007/s11547-019-01064-2
Westover KD, Loo BW, Gerber DE, et al. Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial. Int J Radiat Oncol Biol Phys. 2015;93:72-81. doi:10.1016/j.ijrobp.2015.05.004
Iyengar P, Zhang-Velten E, Court L, et al. Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II/III non-small cell lung cancer and poor performance status: a randomized clinical trial. JAMA Oncol. 2021;7:1497-1505. doi:10.1001/JAMAONCOL.2021.3186
Eze C, Taugner J, Roengvoraphoj O, et al. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis. Radiat Oncol. 2019;14:163. doi:10.1186/s13014-019-1304-2
Eze C, Taugner J, Schmidt-Hegemann NS, et al. Feasibility of hypofractionated radiotherapy in inoperable node-positive NSCLC patients with poor prognostic factors and limited pulmonary reserve: a prospective observational study. Acta Oncol. 2021;60:1-5. doi:10.1080/0284186X.2021.1941244
Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;49:23-33. doi:10.1016/S0360-3016(00)01374-2
Gore EM, Hu C, Sun AY, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12:1561-1570. doi:10.1016/j.jtho.2017.06.015
Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13:671-678. doi:10.1016/S1470-2045(12)70139-0
Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38:706-714. doi:10.1200/JCO.19.01162
Kong F-MS, Hu C, Ten Haken R, et al. NRG-RTOG 1106/ACRIN 6697: a phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC-results and comparison to NRG-RTOG 0617 (nonpersonalized RT dose escalation). J Clin Oncol. 2021;39(15 suppl):8548. doi:10.1200/JCO.2021.39.15_SUPPL.8548
Eze C, Schmidt-Hegemann NS, Sawicki LM, et al. PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging. 2021;48:3975-3989. doi:10.1007/s00259-021-05211-8
Taugner J, Käsmann L, Eze C, et al. Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting. Cancers (Basel). 2021;13:1613. doi:10.3390/CANCERS13071613
Bozorgmehr F, Chung I, Christopoulos P, et al. Thoracic radiotherapy plus durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer. 2020;20:806. doi:10.1186/s12885-020-07264-8
Yamada T, Uchino J, Chihara Y, et al. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). Ther Adv Med Oncol. 2020;12:1758835920927841. doi:10.1177/1758835920927841
Eze C, Lombardo E, Nierer L, et al. (2022). MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients. Radiation Oncology, 17. doi: 10.1186/s13014-022-02011-8